Auto Owners Insurance Co Raises Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Auto Owners Insurance Co dramatically increased its Thermo Fisher Scientific stake in the fourth quarter, ending with 2.43 million shares valued at about $1.41 billion. The stock now makes up 0.3% of the fund’s portfolio.
• Thermo Fisher reported better-than-expected quarterly results, posting EPS of $5.44 versus $5.25 expected and revenue of $11.01 billion versus $10.86 billion estimated. Revenue rose 6.2% year over year, and the company raised FY2026 guidance to $24.64-$25.12 EPS.
• The company’s shares were trading around $465.98, near the lower end of their 12-month range, while analysts overall maintain a Moderate Buy view with an average target price of $608.95. Thermo Fisher also announced a quarterly dividend of $0.47 per share, payable July 15.

Auto Owners Insurance Co grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 57,845.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,427,896 shares of the medical research company's stock after buying an additional 2,423,706 shares during the quarter. Thermo Fisher Scientific accounts for 0.3% of Auto Owners Insurance Co's portfolio, making the stock its 29th largest position. Auto Owners Insurance Co owned about 0.65% of Thermo Fisher Scientific worth $1,406,844,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Howard Capital Management Inc. raised its holdings in Thermo Fisher Scientific by 0.5% in the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company's stock worth $1,791,000 after purchasing an additional 16 shares during the period. Petros Family Wealth LLC raised its position in shares of Thermo Fisher Scientific by 3.9% during the 4th quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company's stock valued at $264,000 after buying an additional 17 shares in the last quarter. Salomon & Ludwin LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock worth $669,000 after purchasing an additional 17 shares during the period. Pallas Capital Advisors LLC increased its position in shares of Thermo Fisher Scientific by 1.5% during the 4th quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company's stock valued at $728,000 after purchasing an additional 18 shares during the last quarter. Finally, Red Door Wealth Management LLC lifted its position in Thermo Fisher Scientific by 0.8% in the fourth quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company's stock worth $1,250,000 after buying an additional 18 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 0.3%

TMO opened at $465.98 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm has a market cap of $173.17 billion, a price-to-earnings ratio of 25.62, a PEG ratio of 2.06 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $643.99. The stock has a fifty day moving average price of $476.59 and a 200-day moving average price of $523.32.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period in the prior year, the firm posted $5.15 earnings per share. The company's quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 10.34%.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent analyst reports. Weiss Ratings reiterated a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating for the company in a research report on Friday, April 24th. Morgan Stanley reissued an "overweight" rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Saturday, May 9th. Finally, KeyCorp reissued an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $608.95.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.